Does Medicare Cover GLP-1 Medications in 2026?
Medicare Part D cannot cover GLP-1s for weight loss — but three separate coverage pathways exist for diabetes, cardiovascular risk, and sleep apnea. Plus: the July 2026 BALANCE pilot.
Medicare operates under a federal statute that prohibits Part D from covering drugs prescribed "solely for weight loss." This is not a policy decision that CMS can override, and it is not a formulary choice that any individual Medicare plan can change. It is federal law — 42 U.S.C. §1395w-102(e)(2) — and it is the reason that no Medicare plan in the country covers Wegovy or Zepbound for obesity management, regardless of how medically necessary the treatment might be.
But the situation is more nuanced than it first appears. Three separate, legitimate coverage pathways exist for Medicare beneficiaries to access GLP-1 medications — and a significant new pilot program, the BALANCE model, is scheduled to launch in July 2026 and will open weight-loss GLP-1 coverage to some Medicare beneficiaries for the first time. This guide explains every pathway available in 2026.
Medicare GLP-1 Coverage at a Glance
| Medication / Indication | Covered? | Key Requirements |
|---|---|---|
| Ozempic (T2D) | Yes — >90% of plans | T2D required; PA on most plans; Tier 2–4; covered by >90% of Part D plans |
| Mounjaro (T2D) | Yes — ~93% of plans | T2D required; PA required; covered by approximately 92.9% of Part D plans |
| Wegovy (Weight Loss) | NO | Federal statutory exclusion. BALANCE model pilot expected July 2026. |
| Zepbound (Weight Loss) | NO | Federal statutory exclusion. |
| Wegovy (CV Risk) | Yes — if plan lists it | Established CVD + BMI ≥27; plan must specifically include Wegovy for CV indication; use cardiovascular ICD-10 codes |
| Zepbound (OSA) | Yes — if plan lists it | AHI ≥15 sleep study + BMI ≥30; plan must list Zepbound for OSA indication |
The Statutory Exclusion Explained
Medicare Part D cannot cover drugs "prescribed solely for weight loss" per 42 U.S.C. §1395w-102(e)(2). This is a congressional statute — passed as part of the Medicare Modernization Act of 2003 — and it explicitly excludes weight loss drugs from Part D coverage. Neither CMS nor any Part D plan administrator can override a federal statute. No amount of medical necessity documentation, appeals, or prescriber argumentation changes this: the exclusion is built into the law itself.
The weight loss exclusion is federal law. It is NOT a Medicare bureaucratic decision that can be appealed or overridden. However, the same medications CAN be covered for other FDA-approved indications — Type 2 diabetes, established cardiovascular disease, and obstructive sleep apnea — under those separate, lawful pathways.
Pathway 1: Diabetes (Most Common)
Ozempic and Mounjaro for Type 2 diabetes management are covered by the overwhelming majority of Medicare Part D plans — over 90% for Ozempic, approximately 93% for Mounjaro. This is the most commonly used GLP-1 pathway for Medicare beneficiaries, and it is well established.
- Required documentation: Documented Type 2 diabetes diagnosis, HbA1c at or above 7%, prior treatment history (typically metformin unless contraindicated), clinical management documentation.
- Cost (Ozempic): Approximately $35–100/month under the 2026 $2,100 annual out-of-pocket cap.
- Cost (Mounjaro): Approximately $35–150/month with the same annual OOP protection.
- OOP cap: The 2026 annual out-of-pocket maximum of $2,100 for Part D is the primary cost protection mechanism for Medicare beneficiaries on high-cost specialty medications.
Prior authorization is required on most plans. Check your specific plan formulary at Medicare.gov's Plan Finder tool to confirm tier placement and PA requirements before your appointment.
Pathway 2: Cardiovascular Risk Reduction (Wegovy Only)
In March 2024, Wegovy (semaglutide) received FDA approval for reducing the risk of serious cardiovascular events — heart attacks, strokes, and cardiovascular death — in adults with established cardiovascular disease and obesity or overweight. This approval created a new, lawful coverage pathway for Medicare Part D because the indication is cardiovascular disease management, not weight loss.
Requirements for Medicare coverage under this pathway:
- Established cardiovascular disease — specifically: prior myocardial infarction (heart attack), prior ischemic stroke, or symptomatic peripheral arterial disease (claudication, prior peripheral vascular surgery or intervention)
- BMI ≥27
- Prescription must document the cardiovascular indication — not weight management — using appropriate cardiovascular ICD-10 codes
- Plan must have added Wegovy for this specific indication to its formulary — not all plans have done so as of 2026
Check your specific plan formulary at Medicare.gov first. Coverage varies by plan, and some Part D plans have been slower to add Wegovy for the CV indication than others.
Pathway 3: Obstructive Sleep Apnea (Zepbound)
In December 2024, Zepbound (tirzepatide) received FDA approval for treating moderate-to-severe obstructive sleep apnea in adults with obesity. Like the CV risk approval for Wegovy, this created a new, lawful Medicare Part D coverage pathway because OSA management — not weight loss — is the approved indication.
Requirements for Medicare coverage under this pathway:
- Moderate-to-severe obstructive sleep apnea confirmed by sleep study — AHI ≥15 events per hour
- BMI ≥30
- Obstructive (not central) sleep apnea confirmed on study
- Sleep study within the past 3 years is generally required for documentation
- Plan must list Zepbound for the OSA indication — not all Part D plans have added it yet
This is a meaningful pathway for many older patients, given the high prevalence of both obesity and sleep apnea in the Medicare-age population. Check your specific plan formulary — and if your plan doesn't yet list Zepbound for OSA, note that Part D plans update formularies annually and this coverage is expanding.
The BALANCE Model: Medicare Weight-Loss GLP-1 Coverage Coming July 2026
In December 2025, CMS announced the BALANCE model — Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth. This is a CMS Innovation Center pilot program that, starting in July 2026, will allow certain Medicare beneficiaries to access GLP-1 medications specifically for weight management for the first time. The BALANCE model is authorized under CMS's Innovation Center authority, which allows departure from standard Part D rules for approved demonstration projects.
- Phase 1 eligibility: BMI ≥27 plus at least one of: established cardiovascular disease, prediabetes, or hypertension
- Estimated patient copay: Approximately $50/month for participating beneficiaries
- Start date: July 2026
- Enrollment: Details on how to enroll are still being finalized by CMS as of March 2026
Attention Medicare beneficiaries: If you have BMI ≥27 and cardiovascular disease, prediabetes, or hypertension, watch for BALANCE model enrollment information in mid-2026. Ask your provider to flag you for enrollment when it opens. This is a pilot program, not universal coverage — it will involve specific participating sites and eligibility verification.
The BALANCE model is an important development but is still a limited pilot program, not a comprehensive policy change. Full Medicare coverage of weight-loss GLP-1s would require an act of Congress to amend the statutory exclusion in 42 U.S.C. §1395w-102(e)(2). The BALANCE model works around the exclusion via the Innovation Center's demonstration authority — a narrower mechanism.
The Manufacturer Savings Card Restriction
Novo Nordisk and Eli Lilly offer manufacturer savings cards that can reduce patient out-of-pocket costs for Wegovy and Zepbound to as little as $25 per month for commercially insured patients. Medicare beneficiaries cannot use these cards.
The reason is federal anti-kickback law. The federal Anti-Kickback Statute prohibits pharmaceutical manufacturers from offering discounts or subsidies to federally insured patients (Medicare or Medicaid) because such arrangements could induce utilization and inflate federal costs. This prohibition is strictly enforced and applies regardless of the patient's financial situation. The $2,100 annual out-of-pocket cap under Part D (2026) is the primary cost protection mechanism available to Medicare beneficiaries.
Estimated Costs for Medicare Beneficiaries
Ozempic (T2D, Part D)
$2,100 annual OOP cap. No manufacturer savings cards.
Mounjaro (T2D, Part D)
$2,100 annual OOP cap. No manufacturer savings cards.
Wegovy (CV Risk)
Check plan formulary at Medicare.gov. Not all plans include it for CV indication.
Zepbound (OSA)
Check plan formulary at Medicare.gov. Coverage expanding in 2026.
Common Questions From Medicare Beneficiaries
I have Medicare. Can I get Ozempic for weight loss?
Medicare does not cover any GLP-1 medication for weight loss due to the federal statutory exclusion in 42 U.S.C. §1395w-102(e)(2). This cannot be appealed or overridden. However, if you have Type 2 diabetes, you may qualify for Ozempic coverage under the diabetes indication — which is covered by over 90% of Part D plans. If you have established cardiovascular disease, Wegovy may be covered for CV risk reduction. If you have obstructive sleep apnea, Zepbound may be covered for OSA.
What's the BALANCE model and when can I enroll?
The CMS BALANCE pilot program begins in July 2026 and will allow some Medicare beneficiaries with BMI ≥27 plus cardiovascular disease, prediabetes, or hypertension to access weight-loss GLP-1 medications for the first time. The estimated patient copay is approximately $50/month. Enrollment details are still being finalized by CMS as of March 2026. Ask your provider to flag you for enrollment when information becomes available in mid-2026.
Does Medicare Advantage cover GLP-1s differently?
Medicare Advantage plans follow the same federal statutory exclusion for weight loss coverage — they cannot cover GLP-1s for obesity any more than traditional Medicare can. However, some Medicare Advantage plans have added extra supplemental benefits and may cover certain conditions or services that traditional Medicare does not. The three legitimate pathways — diabetes, cardiovascular risk, and sleep apnea — generally work the same way across both traditional Medicare and Medicare Advantage Part D. Check directly with your specific plan, as formulary details vary.
Related GLP-1 Coverage Guides
Medicare Beneficiary? We Know GLP-1 Coverage Pathways.
If you have Type 2 diabetes, established cardiovascular disease, or obstructive sleep apnea, GLP-1 therapy may be covered under Medicare. We'll help you navigate which pathway applies.
Or call us: (206) 960-4770 · Seattle · Kirkland · Federal Way